{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21,522"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Reported as descriptive results. The combined CGH array and exome data will be mined to identify genes and pathways that are targeted by select somatic events in each of the patient subsets.","groups":[{"description":"Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nVorinostat: Given PO","id":"OG000","title":"Treatment (Vorinostat)"}],"paramType":"NUMBER","populationDescription":"One of the cases that had FFPE blocks for the study.","reportingStatus":"POSTED","timeFrame":"Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months","title":"The Number of Genes Sequenced in the WES Assay as a Measure of the Whole Exome Profile of the Sorted Tumor Population and Matching Germ Line Sample","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Genes sequenced in the WES assay."}